. 2021 Jan 27;6(1):e01026-20. doi: 10.1128/mSphere.01026-20

TABLE 2.

Genotypic characteristics of 195 CNSPA isolates

Parameter	C/T-nonsusceptible isolates (n = 121)		C/T-susceptible isolates (n = 74)
Parameter	Carbapenemase producers (n = 86)	Non-carbapenemase producers (n = 35)	C/T-susceptible isolates (n = 74)
No. of STs	12	14 (13 + 1 new)	58 (55 + 3 new)
Known STs^a	233, 235, 244, 308, 316, 357, 621, 773, 823, 964, 3440, 3444	155, 179, 235, 244, 252, 274, 313, 316, 357, 664, 815, 1076, 1666	11, 17, 27, 111, 155, 207, 235, 244, 245, 253, 266, 274, 292, 298, 314, 357, 389, 408, 446, 463, 471, 485, 508, 553, 560, 564, 569, 606, 620, 645, 697, 708, 773, 792, 815, 840, 882, 1076, 1247, 1649, 1930, 2013, 2021, 2033, 2069, 2326, 2476, 2651, 3078, 3311, 3439, 3442, 3443, 3445, 3446
Harbors acquired β-lactamase	10	24	5
AmpC and regulator alteration^b	10	6
PBP3 alteration^b	3	1
Ceftazidime/avibactam susceptible	4	10	66

STs in bold were observed only in the C/T-nonsusceptible population in our study.

Only alterations unique to the C/T-nonsusceptible population are reported. Refer to Fig. 1 and 2 for the specific observed alterations for each isolate.